Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) EBIT (2016 - 2023)

Historic EBIT for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $53.8 million.

  • RedHill Biopharma's EBIT rose 48687.63% to $53.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$44.0 million, marking a year-over-year increase of 5531.84%. This contributed to the annual value of -$14613.0 billion for FY2024, which is 11568249392.02% down from last year.
  • RedHill Biopharma's EBIT amounted to $53.8 million in Q2 2023, which was up 48687.63% from -$29.1 million recorded in Q1 2023.
  • RedHill Biopharma's 5-year EBIT high stood at $53.8 million for Q2 2023, and its period low was -$141.6 million during Q4 2021.
  • Over the past 5 years, RedHill Biopharma's median EBIT value was $12.4 million (recorded in 2019), while the average stood at $421000.0.
  • Per our database at Business Quant, RedHill Biopharma's EBIT tumbled by 81834.28% in 2021 and then skyrocketed by 48687.63% in 2023.
  • RedHill Biopharma's EBIT (Quarter) stood at $11.8 million in 2019, then soared by 67.53% to $19.7 million in 2020, then crashed by 818.34% to -$141.6 million in 2021, then surged by 46.5% to -$75.7 million in 2022, then skyrocketed by 170.97% to $53.8 million in 2023.
  • Its last three reported values are $53.8 million in Q2 2023, -$29.1 million for Q1 2023, and -$75.7 million during Q4 2022.